InSysBio announces its participation in SITC’s 39th Annual Meeting which is to be held from November 6-10, 2024, at George R. Brown Convention Center in Houston, TX, USA. InSysBio team is going to present its Mechanistic modeling services and tools to support development of immunotherapies at Booth #1032 and 3 posters in frames of the Meeting, namely:

Saturday, November 9:

• 536 "Evaluation of various strategies to unleash DNAM1 signaling and block TIGIT/PVRIG axis" by Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
• 1064 "Mechanistic translational modeling to predict first-in-human dose for T-cell engager: HPN536 case study" by Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
• 1208 "Comparison of receptor occupancy and optimal doses of PD1xCD40 and PDL1xCD40 bispecific antibodies using physiologically based pharmacokinetic modeling" by Alexandra Diakonova, Dmitry Schelokov, Oleg Demin Jr, Oleg Demin

Check out Booth #1032 and posters at SITC 2024 Annual Meeting!

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com

Share